D. Boral Capital Reiterates “Buy” Rating for GeoVax Labs (NASDAQ:GOVX)

D. Boral Capital reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report released on Monday morning,Benzinga reports. They currently have a $9.00 price target on the stock.

Several other brokerages have also recently weighed in on GOVX. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a report on Wednesday, April 16th. Alliance Global Partners cut their price objective on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating for the company in a report on Tuesday, April 15th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $11.10.

GeoVax Labs Price Performance

Shares of GOVX opened at $1.32 on Monday. The stock has a market cap of $20.06 million, a price-to-earnings ratio of -0.36 and a beta of 3.45. The company has a 50-day moving average of $1.00 and a two-hundred day moving average of $1.57. GeoVax Labs has a one year low of $0.73 and a one year high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.14. The firm had revenue of $1.64 million during the quarter, compared to the consensus estimate of $0.75 million. Analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current year.

Institutional Trading of GeoVax Labs

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the period. Northern Trust Corp purchased a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $29,000. Citadel Advisors LLC purchased a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $104,000. Armistice Capital LLC purchased a new position in shares of GeoVax Labs during the first quarter valued at approximately $703,000. Finally, Jane Street Group LLC purchased a new position in shares of GeoVax Labs during the first quarter valued at approximately $27,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.